Aristea Therapeutics Was A Clinical Stage Biopharmaceutical Company Based In San Diegocaliforniafounded In 2018The Company Focused On Developing Innovative Therapies For Serious Inflammatory Orphan Diseasesits Lead Drug Candidaterist4721Was A Cxcr2 Antagonist Aimed At Treating Dermatological And Rheumatic Conditionsincluding Palmoplantar Pustulosisppp The Company Also Explored Treatments For Familial Mediterranean Feverfmfand Behasetae S Disease Aristea Therapeutics Raised A Total Of $78 Million Through Series B Financing And Partnershipsincluding A Collaboration With Arena Pharmaceuticals In 2021This Partnership Involved A Significant Upfront Payment And An Equity Investmentalong With An Exclusive Acquisition Option Following The Phase 2B Trial For Pppunfortunatelythe Company Ceased Operations In February 2023 After Halting Its Lead Drug Candidate Due To Safety Concerns And Was Unable To Secure Viable Strategic Alternatives
